Please login to the form below

Not currently logged in

S-A collaborates to develop antibodies

S-A has entered into a global collaboration agreement to develop an antibody against an antigen present on the surface of carcinoma cells

Sanofi-aventis (S-A) has entered into a global collaboration agreement with Micromet to develop an antibody against an antigen present on the surface of carcinoma cells.

Under the terms of the agreement, Micromet will take responsibility for discovery, research and development of the antibody through the phase I clinical trial process, under the supervision of a Joint Steering Committee. Further development and worldwide commercialisation of the antibody will be sanofi-aventis' responsibility.

Upon signing the agreement, S-A will make an upfront payment of €8m to Micromet. Additionally, Micromet will be eligible for up to €312m in milestone and royalty payments.

"Micromet's BiTE antibodies represent a promising new approach to treating cancer," declared Marc Cluzel, senior vice-resident R&D, sanofi-aventis. "We believe BiTE antibodies have the potential to significantly expand the treatment options that we can offer to cancer patients in the future."

29th October 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....